RESEARCH ARTICLE

REVISED β -lactamases (*bla*_{TEM}, *bla*_{SHV}, *bla*_{CTXM-1}, *bla*_{VEB}, *bla*_{OXA-1}) and class C β -lactamases gene frequency in *Pseudomonas aeruginosa* isolated from various clinical specimens in Khartoum State, Sudan: a cross sectional study [version 2; peer review: 2 approved]

Previously titled: Extended spectrum β -lactamases and class C β -lactamases gene frequency in *Pseudomonas aeruginosa* isolated from various clinical specimens in Khartoum State, Sudan: a cross sectional study

Dina N. Abdelrahman ^{1,2}, Aya A. Taha², Mazar M. Dafaallah²,
Alaa Abdelgafoor Mohammed³, Abdel Rahim M. El Hussein ¹,
Ahmed I. Hashim ², Yousif F. Hamedelnil², Hisham N. Altayb ⁴

¹Department of Virology, Central Laboratory, Khartoum, Sudan

²Department of Microbiology, College of Medical Laboratory Sciences, Sudan University of Science and Technology, Khartoum, Sudan

³Department of Pharmaceutical Biotechnology, College of Pharmacy, Ahfad University for Women, Omdurman, Khartoum, Sudan

⁴Biochemistry Department, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia

V2 First published: 27 Jul 2020, 9:774
<https://doi.org/10.12688/f1000research.24818.1>
Second version: 15 Sep 2020, 9:774
<https://doi.org/10.12688/f1000research.24818.2>
Latest published: 01 Apr 2021, 9:774
<https://doi.org/10.12688/f1000research.24818.3>

Abstract

Background: *Pseudomonas aeruginosa* is a pathogenic bacterium, causing nosocomial infections with intrinsic and acquired resistance mechanisms to a large group of antibiotics, including β -lactams. This study aimed to determine the susceptibility pattern to selected antibiotics and to index the first reported β -lactamases gene (extended spectrum β -lactamases (ESBLs) genes and class C β -lactamases genes) frequency in *Ps. aeruginosa* in Khartoum State, Sudan.

Methods: 121 *Ps. aeruginosa* clinical isolates from various clinical specimens were used in this cross-sectional study conducted in Khartoum State. A total of 80 isolates were confirmed as *Ps. aeruginosa* through conventional identification methods and species-specific primers (the remaining 40 isolates were other bacterial

Open Peer Review

Approval Status

	1	2
version 3 (revision) 01 Apr 2021		
version 2 (revision) 15 Sep 2020	 view	 view
version 1 27 Jul 2020	 view	
1. Nobumichi Kobayashi , Sapporo Medical		

species). The susceptibility pattern of the confirmed isolates to selected antibiotics was done following the Kirby Bauer disk diffusion method. Multiplex PCR was used for detection of seven β -lactamase genes (*bla*_{TEM}, *bla*_{SHV}, *bla*_{CTXM-1}, *bla*_{VEB}, *bla*_{OXA-1}, *bla*_{AmpC} and *bla*_{DHA}).

Results: Of the 80 confirmed *Ps. aeruginosa* isolates, 8 (10%) were resistant to Imipenem while all isolates were resistant to Amoxicillin and Amoxycylav (100%). A total of 43 (54%) *Ps. aeruginosa* isolates were positive for ESBLs genes, while 27 (34%) were positive for class C β -lactamases, and 20 (25%) were positive for both classes. Frequency of ESBLs genes was as follows: *bla*_{TEM}, 19 (44.2%); *bla*_{SHV}, 16 (37.2%); *bla*_{CTXM-1}, 10 (23.3%); *bla*_{VEB}, 14 (32.6%); and *bla*_{OXA-1}, 7 (16.3%). Occurrence of class C β -lactamases genes was *bla*_{AmpC} 22 (81.5%) and *bla*_{DHA} 8 (29.6%). In total, 3 (11.1%) isolates were positive for both *bla*_{AmpC} and *bla*_{DHA} genes.

Conclusion: *Ps. aeruginosa* isolates showed a high rate of β -lactamases production, with co-resistance to other antibiotic classes. The lowest resistance rate of *Ps. aeruginosa* was to Imipenem followed by Gentamicin and Ciprofloxacin. No statistically significant relationship between production of β -lactamases in *Ps. aeruginosa* and resistance to third generation cephalosporins was found.

Keywords

ESBLs, class C β -lactamase, Polymerase Chain Reaction, *Ps. aeruginosa*, pyocyanin pigment, Khartoum-Sudan.

This article is included in the **Pathogens** gateway.

University School of Medicine, Sapporo, Japan

2. **Muhammad Qasim**, Kohat University of Science and Technology, Kohat, Pakistan

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Dina N. Abdelrahman (Dinadi456@outlook.com)

Author roles: **Abdelrahman DN:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation; **Taha AA:** Investigation, Methodology, Resources, Validation, Visualization; **Dafaallah MM:** Investigation, Methodology, Resources, Visualization; **Mohammed AA:** Investigation, Visualization; **El Hussein ARM:** Writing – Review & Editing; **Hashim AI:** Investigation, Methodology, Software, Writing – Review & Editing; **Hamedelnail YF:** Conceptualization, Investigation, Methodology, Supervision; **Altayb HN:** Conceptualization, Data Curation, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2020 Abdelrahman DN *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Abdelrahman DN, Taha AA, Dafaallah MM *et al.* β -lactamases (*bla*_{TEM}, *bla*_{SHV}, *bla*_{CTXM-1}, *bla*_{VEB}, *bla*_{OXA-1}) and class C β -lactamases gene frequency in *Pseudomonas aeruginosa* isolated from various clinical specimens in Khartoum State, Sudan: a cross sectional study [version 2; peer review: 2 approved] F1000Research 2020, 9:774 <https://doi.org/10.12688/f1000research.24818.2>

First published: 27 Jul 2020, 9:774 <https://doi.org/10.12688/f1000research.24818.1>

REVISED Amendments from Version 1

- Due to the change in the classification of *bla*_{TEM}, *bla*_{SHV}, *bla*_{CTXM-1}, *bla*_{VEB} and *bla*_{OXA-1}, from ESBLs to β-lactamases enzymes generally, they named in the draft as individual genes and classified as β-lactamases group. This change was applied in the whole draft including tables and figures, even the title changed to “β-lactamases (*bla*_{TEM}, *bla*_{SHV}, *bla*_{CTXM-1}, *bla*_{VEB}, *bla*_{OXA-1}) and class C β-lactamases gene frequency in *Pseudomonas aeruginosa* isolated from various clinical specimens in Khartoum State, Sudan: a cross sectional study”

- In abstract: The sample size mentioned as the confirmed 80 *P. aeruginosa* isolates, the remaining 41 isolate other than *P. aeruginosa* deleted.

- All “*Ps. aeruginosa*” in the text changed to “*P. aeruginosa*” as formal abbreviation.

- All “Amoxyclav” in the text changed to “amoxicillin/clavulanate”

- “Class AmpC genes” in Figure 5 changed to “Class C β-lactamase”

- “ESBLs” changed to “β-lactamases” in Figure 3 and Figure 5.

Any further responses from the reviewers can be found at the end of the article

Introduction

Pseudomonas aeruginosa is one of the leading causes of nosocomial infections worldwide with high mortality rates, particularly among immunocompromised patients¹. *P. aeruginosa* infections are difficult to treat, due to its extraordinary antimicrobial resistance to all available classes of antimicrobial agents², including β-lactams, aminoglycosides and fluoroquinolones³. Resistance to β-lactams occurs by different mechanisms, including *bla*_{AmpC} overexpression due to genetic mutations, mutant gene acquisition, overproduction of efflux system, or low permeability³. β-lactamases refer to enzymes that hydrolyze the amide bond of the β-lactam ring leading to drug inactivation and therapy failure⁴. β-lactamases are classified molecularly into four groups: class A (extended spectrum β-lactamases (ESBLs)), class B (metallo-β-lactamases), class C (cephalosporinases), and class D (oxacillinases)⁵.

ESBLs are enzymes that extend their hydrolyzing ability to hydrolyze broad spectrum cephalosporins⁶ and they also confer resistance to penicillins and narrow spectrum cephalosporins³. ESBLs are inhibited by β-lactamase inhibitors, such as clavulanic acid⁷. β-lactamases are transformed to ESBLs usually after point mutations in the β-lactamases gene. These mutations alter the substrate specificity because of changes in the amino acid sequences near the enzyme active site⁵. ESBLs producing *P. aeruginosa* have been reported worldwide in different countries^{8–17}.

AmpC β-lactamases are class C cephalosporinases that mediate bacterial resistance to cephalosporins and cephamycins. They also exhibit low rates of monobactam, cefepime and carbapenem hydrolysis¹⁸ and usually resist the inhibition by clavulanic acid⁴. Normally, AmpC is a chromosomal β-lactamase gene that is regulated by *ampR* gene and expressed constantly. Point

mutations of *ampR* gene in *Enterobacter cloacae* activate AmpC that mediate resistance to β-lactams¹⁹. In *P. aeruginosa* over expressed AmpC β-lactamase mediate the resistance to broad spectrum cephalosporins³. AmpC β-lactamase in *P. aeruginosa* has also been reported in different countries around the world^{20–27}.

The exact frequency of β-lactamase producing *P. aeruginosa* in Khartoum State, Sudan is unknown; therefore, the aim of this study was to determine the susceptibility pattern to selected antibiotics and to determine the frequency of β-lactamases producing *P. aeruginosa* isolates collected in Khartoum State hospitals.

Methods

Study design

This is a cross-sectional study conducted between February 2017 and October 2017. Ethical approval for the study was obtained from the ethical committee of the College of Medical Laboratory Science, Sudan University of Science and Technology (SUST) (ethical meeting no, SUST/DSR/IEC/EA2/2017; data, 07th January 2017). Written informed consent from participants was waived by the same ethical committee as the study only used previously collected human bio-specimens with limited participant data.

Collection and identification of bacterial strains

A total of 121 clinical isolates, which initially identified as *P. aeruginosa* and bacteria other than *P. aeruginosa* was excluded. Selected isolates were obtained from Soba Teaching Hospital, Elribat University Hospital, National Laboratory for Public Health, Ear Nose Throat Hospital, and Military Hospital in Khartoum State. When there was a positive confirmation of *P. aeruginosa*, the study supervisor went and collected the sample from the hospital. The samples were collected from patients suffering from urinary tract infections, respiratory tract infections, blood infections, and wound and ear infections. Data pertaining to the site of infection was collected from hospital records. The bacteria were preserved in 20% glycerol and peptone water and stored at -20°C

Phenotypic identity of the isolates was confirmed through conventional bacterial identification methods, such as Gram stain, oxidase test, and reactions in media containing sugars, such as Kligler Iron Agar, urease test and, citrate test. Pigment production was assessed using Muller Hinton agar, and then phenotypic identity confirmed by genotypic characterization using multiplex PCR, as previously described¹.

Antimicrobial susceptibility testing

Muller Hinton medium (HiMedia, India) was prepared and sterilized as instructed by the manufacturer. Antimicrobial susceptibility testing was performed following the modified Kirby-Bauer disc diffusion method¹ and the results interpreted according to Clinical Laboratory Standards Institute guidelines (CLSI, 2007). The following antimicrobial discs (HiMedia, India) were used for sensitivity testing: Amoxicillin (25 µg), Cefotaxime (30 µg), Amoxicillin-Clavulanic acid (30 µg), Gentamicin (10 µg), Ciprofloxacin (5 µg), Chloramphenicol (30 µg) and

Imipenem (10 µg). *P. aeruginosa* ATCC 27853 was used as quality control strain to control the performance of the test and ensure that the test is properly performed.

Phenotypic identity of the isolates was confirmed through conventional bacterial identification methods such as Gram stain, oxidase test, reactions in media containing sugars such as Kligler Iron Agar, urease test and citrate test.

Genotypic analysis of bacterial isolates

Genomic DNA was extracted by simple boiling method¹⁸. The extracted DNA was used as a template for amplification of target genes using multiplex PCR using TECHNE TC-312 (UK) thermocycler. Firstly, *oprI* and *oprL* primers (Table 1) (Macrogen, Korea) were used to confirm the identification of *P. aeruginosa*. Seven primer pairs (Table 1) (Macrogen, Korea) were used for detection of β -lactamases genes (*bla*_{TEM}, *bla*_{SHV}, *bla*_{CTXM-1}, *bla*_{VEB}, *bla*_{OXA-1}) and class C genes (*bla*_{AmpC} and *bla*_{DHA}). The *oprI* and *oprL* reaction was carried out with the following cycling conditions: denaturation at 95°C for 5 min; 33 cycles of denaturation at 95°C for 30 secs, annealing at 58°C for 30 sec and extension at 72°C for 30 secs, and final extension at 72°C for 5 min²⁸.

β -lactamases detection was done in two batches; the first batch was used for detection of *bla*_{TEM}, *bla*_{SHV}, *bla*_{CTXM-1}, *bla*_{AmpC} and *bla*_{DHA}, while the second batch was used for detection of *bla*_{VEB} and *bla*_{OXA-1} genes. The first batch detection was done in 20 µl of final reaction mixture using Maxime PCR Premix kits (iNtRON Biotechnology, Korea), containing 13 µl of double distilled water (DDW), 0.3 µl of each five forward and 0.3 µl of each five reverse primers (1.5 µl), 2 µl of Dimethyl sulfoxide (DMSO) and 2 µl of template DNA.

Amplification of the second batch was done in 20 µl using Maxime PCR Premix kits (iNtRON Biotechnology, Korea), containing 14.4 µl of DDW, 0.4 µl of each two forward and 0.4 µl of each two reverse primers (0.8 µl), 2 µl of DMSO and 2 µl of template DNA. Cycling conditions for both amplification reactions were as follows: initial denaturation at 94°C for 2 minutes, then 35 cycles of denaturation at 94°C for 30 secs, annealing at 54°C for 30 secs and extension at 72°C for 50 secs, and final extension at 72° for 5 minutes.

Amplified products were analyzed by electrophoreses at 80 volts for 20 minutes on 1.5% agarose gel containing ethidium bromide

Table 1. Primer sequences.

Target gene	Primers	Sequences (5'-3')	Product size (bp)	References
<i>oprI</i>	F	ATGAACAACGTTCTGAAATTC	250	29
	R	CTTGCGGCTGGCTTTTCCAG		
<i>oprL</i>	F	ATGGAAATGCTGAAATTCGGC	500	29
	R	CTTCTTCAGCTCGACGCGACG		
<i>TEM</i>	F	ATGAGTATTCAACATTTCCGTG	861	30
	R	TTACCAATGCTTAATCAGTGAG		
<i>SHV</i>	F	TTTATGGCGTTACCTTTGACC	1050	30
	R	ATTTGTCGCTCTTTACTCGC		
<i>CTXM-1</i>	F	GACGATGCTCACTGGCTGAGC	499	31
	R	AGCCGCCGACGCTAATACA		
<i>AmpC</i>	F	ATCAAACTGGCAGCCG	550	32
	R	GAGCCCGTTTATGGACCCA		
<i>DHA</i>	F	AACTTTCACAGGTGTGCTGGGT	405	33
	R	CCGTACGCATACTGGCTTTGC		
<i>VEB</i>	F	CATTCCCGATGCAAAGCGT	648	34
	R	CGAAGTTTCTTTGGACTCTG		
<i>OXA-1</i>	F	GGCACCAGATTCAACTTTCAAG	564	35
	R	GACCCCAAGTTTCCTGTAAGTG		

and then visualized using UV transilluminator (Uvitec–UK) with 50bp or 100bp molecular DNA ladder (iNtRON Biotechnology, Korea).

Data analysis

Statistical analysis of the data was performed using chi-square test (level of significance was 0.05) with SPSS software version 20 and GraphPad prism 5 demo.

Results

From 121 clinical isolates collected from different hospitals in Khartoum State, only 80 (66%) were confirmed as *P. aeruginosa* through conventional methods and species-specific primers; the remaining 41 (34%) isolates were considered as other Gram-negative rod bacteria. The distribution of clinical isolates according to site of infection was as follows: urine, 34 (42%); wound swab, 24 (30%); ear swab, 8 (10%); sputum, 8 (10%); and blood, 6 (7.5%).

The results of antimicrobial susceptibility test for selected antibiotics are presented in Table 2.

Out of 80 *P. aeruginosa* isolates, 54 (68%) were Pyocyanin pigment producers, while 26 (32%) were not pigment producers. There was a significant association between pyocyanin pigment production and site of infection ($P=0.000$) (Figure 1). There was also a significant association between pigment production and resistance to Chloramphenicol ($P=0.020$) and Cefotaxime ($P=0.000$), while there was insignificant association between pigment production and resistance to other antimicrobials used in this study (Figure 2).

Molecular detection of β -lactamases showed that 43 (54%) of the isolates were positive for at least one β -lactamases gene, while 37 (46%) were negative for all genes (Figure 3). The

frequency of each gene presence among *P. aeruginosa* was as follows: bla_{TEM} , 19 (44.2%); bla_{SHV} , 16 (37.2%); bla_{CTX-M1} , 10 (23.3%); bla_{VEB} , 14 (32.6%); and bla_{OXA-1} , 7 (16.3%). There was a significant association between the presence of bla_{TEM} , bla_{SHV} , bla_{CTX-M1} , bla_{VEB} or bla_{OXA-1} genes in *P. aeruginosa* and site of infection ($P=0.030$) (Figure 3). Co-presence of more than one of bla_{TEM} , bla_{SHV} , bla_{CTX-M1} , bla_{VEB} or bla_{OXA-1} gene among *P. aeruginosa* clinical isolates is presented in Table 3.

Class C β -lactamases gene were positive in 27 (34%) *P. aeruginosa* isolates; while 53 (66%) were negative (Figure 4). The frequency of class C β -lactamases genes was as follows: bla_{AmpC} , 22 (81.5%); bla_{DHA} , 8 (29.6%); and 3 (11.1%) isolates were positive for both genes. Association between presence of Class C β -lactamases genes and site of infection was insignificant ($P=0.215$) (Figure 4).

Table 2. Antimicrobial susceptibility pattern of *Pseudomonas aeruginosa* (n=80).

Antimicrobial agent	Susceptible isolates	Resistant isolates
Ciprofloxacin	57 (71.2)	23 (28.8)
Gentamicin	61 (76.2)	19 (23.8)
Imipenem	72 (90)	8 (10.0)
Chloramphenicol	9 (11.2)	71 (88.8)
Amoxicillin/clavulanate	0	80 (100)
Amoxicillin	0	80 (100)
Ceftazidime	34 (42.5)	46 (57.5)
Cefotaxime	9 (11.2)	71 (88.8)

Figure 1. Frequency of *Pseudomonas aeruginosa* pigment producing isolates according to site of infection.

Figure 2. Frequency of *Pseudomonas aeruginosa* pigment producing isolates according to antimicrobial resistance.

Figure 3. Presence of β -lactamases (bla_{TEM} , bla_{SHV} , bla_{CTXM-P} , bla_{VEB} or bla_{OXA-1}) among *Pseudomonas aeruginosa* isolates site of infection.

Table 3. Number of *Pseudomonas aeruginosa* isolates exhibiting co-presence of bla_{TEM} , bla_{SHV} , bla_{CTXM-P} , bla_{VEB} , bla_{OXA-1} β -lactamases genes.

	bla_{TEM}	bla_{SHV}	bla_{CTXM-1}	bla_{VEB}	bla_{OXA-1}
bla_{TEM}	7	6	5	3	1
bla_{SHV}	6	4	4	4	1
bla_{CTXM-1}	5	4	0	1	1
bla_{VEB}	3	4	1	3	3
bla_{OXA-1}	1	1	1	3	2

Figure 4. Presence of class C genes among *Pseudomonas aeruginosa* isolates and site of infection.

In total, 25% of *P. aeruginosa* isolates were positive for both β -lactamase (bla_{TEM} , bla_{SHV} , bla_{CTXM-1} , bla_{VEB} or bla_{OXA-1}) and class C β -lactamase genes (Figure 5). Co-presence of β -lactamase genes and class C β -lactamase among *P. aeruginosa* clinical isolates is presented in Table 4.

Discussion

Pseudomonas aeruginosa is one of the main causative agents of serious nosocomial infections with increased reports of β -lactams resistant strains that makes treatment difficult and complicated¹⁹. Production of β -lactamases is one of the most common mechanisms of β -lactam resistance³⁶.

In this study the frequency of β -lactamases genes among *P. aeruginosa* isolates was 53.8%. This frequency is close to a report from India by Qureshi and Bhatnagar (2016)³⁷, where the frequency of β -lactamases in *P. aeruginosa* isolates was 46%. However, the results of this study disagree with another report from India by Gupta *et al.* (2016)³⁸ where the frequency of β -lactamases in *P. aeruginosa* isolates was 22.9%. These discrepancies could be due to differences in strains of the clinical isolates, the antibiotics used or sample size.

The most abundant gene among the β -lactamases bla_{TEM} , bla_{SHV} , bla_{CTXM-1} , bla_{VEB} , bla_{OXA-1} producing *P. aeruginosa* isolates detected in this study was bla_{TEM} gene (19, 44.2%), followed by bla_{SHV} , bla_{VEB} , bla_{CTXM-1} and bla_{OXA-1} (16 (37.2%), 14 (32.6%), 10 (23.3%) and 7 (16.3%), respectively). Similar results were reported by Salah *et al.* (2016)³⁹ in Egypt concerning the presence of bla_{TEM} , bla_{SHV} and bla_{OXA-1} (50%, 33% and 17%, respectively). The frequency of bla_{TEM} gene is also similar to that reported by Rafiee *et al.* (2014)⁴⁰, which was present

in 39.2% of isolates. In a study in Iran by Sales *et al.* (2017)⁴¹, similar results were reported concerning the presence of bla_{CTXM-1} (27.3%), while in India Jamali *et al.* (2017)¹⁵ reported a higher frequency (57.5%) of this gene.

On the other hand, the frequency of bla_{VEB} and bla_{SHV} genes in this study differs from that reported in Iran by Bokaeian *et al.* (2014)⁴² where bla_{VEB} gene frequency was 13.3%, while the frequency of bla_{SHV} gene was 6.6%. The report by Jamali *et al.* (2017)¹⁵ concerning the genes bla_{TEM} (15%) and bla_{SHV} (75%) are also different from those reported in this study, and this could be due to the variation in strains of clinical isolates and the sample size used.

In this study, the frequency of class C β -lactamase genes in *P. aeruginosa* isolates was 27 (34%). This result is close to a report from India by Gupta *et al.* (2016)³⁸ where 43% of *P. aeruginosa* were AmpC producers, and disagrees with a report from Thailand by Katvoravutthichai *et al.* (2016)⁴³ where 11% of *P. aeruginosa* isolates were AmpC producers. In this study, out of the class C β -lactamase producing *P. aeruginosa* isolates, 22 (81.5%) and 8 (29.6%) isolates were positive for bla_{AmpC} and bla_{DHA} genes, respectively. Qureshi and Bhatnagar (2016)³⁷ in India reported that no *P. aeruginosa* isolates were positive for bla_{AmpC} gene, while Rafiee *et al.* (2014)⁴⁰ in Iran reported that 60.8% of *P. aeruginosa* were positive for bla_{AmpC} gene.

All *P. aeruginosa* clinical isolates tested in our study were resistant to Amoxicillin and Amoxicillin/clavulanate and this may be due to the misuse of antibiotics in Sudan⁴⁴, where plenty of antimicrobial agents are sold over the counter. This

Figure 5. Distribution of β-lactamases (*bla_{TEM}*, *bla_{SHV}*, *bla_{CTXM-P}*, *bla_{VEB}*, *bla_{OXA-1}*) and class C β-lactamase genes among *Pseudomonas aeruginosa* isolates.

Table 4. Number of *P. aeruginosa* isolates exhibiting β-lactamases (*bla_{TEM}*, *bla_{SHV}*, *bla_{CTXM-P}*, *bla_{VEB}*, *bla_{OXA-1}*) and class C genes.

Number of genes	β-lactamases	Class C	Both classes	Total
1	16	6	-	22
2	7	1	9	17
3	-	-	6	6
4	-	-	5	5
5	-	-	1	1
6	-	-	-	0
7	-	-	-	0

Number of genes per isolate*

rate of resistance is higher than the rate of resistance reported by Ahmad *et al.* (2016)⁴⁵ in Pakistan where the resistance to Amoxicillin and Amoxicillin/clavulanate was 73.4% and 67.7% respectively, and this could be justified by the time difference between the studies, as well as the difference in the strains and antibiotics used.

The resistance rate of *P. aeruginosa* to Imipenem was 10% (n=8). This may be due to the infrequent use of Imipenem antibiotics. This percentage agrees with a study reported in Pakistan by Ahmad *et al.* (2016)⁴⁵ where 11.1% of *P. aeruginosa* isolates were resistant to Imipenem, while in Sudan Altom and Ahmed (2015)⁴⁶ reported that 5.7% *P. aeruginosa* isolates were resistant to Imipenem. This finding may indicate that carbapenem resistance is on the rise in *P. aeruginosa* isolates from Sudan.

In this study, the number of *P. aeruginosa* isolates resistant to Cefotaxime, Chloramphenicol and Ceftazidime was 71 (88.8%), 71 (88.8%) and 46 (57.5%), respectively. The rate of resistance to Cefotaxime in this study is different from that reported in Pakistan by Ahmad *et al.* (2016)⁴⁵ who found that 20.3% of *P. aeruginosa* isolates were resistant to Ceftazidime. The resistance rate in this study also disagrees with that reported by Albadawi (2010)⁴⁷ in Sudan who found that resistance of *P. aeruginosa* to Ceftazidime and Cefotaxime were 31% and 42%, respectively. These findings also indicate the rapidly increasing rates of *P. aeruginosa* resistance to antimicrobial agents in Sudan perhaps due to antibiotic misuse.

In this study, 23 (28.8%) and 19 (23.8%) of *P. aeruginosa* clinical isolates were resistant to Ciprofloxacin and Gentamicin, respectively. Altom and Ahmed (2015)⁴⁶ in Sudan also reported that 18.6% of *P. aeruginosa* were resistant to Gentamicin. Different results were reported by Ahmad *et al.* (2016)⁴⁵, where the percentage of resistance to Gentamicin and Ciprofloxacin were 74.3% and 44%, respectively. These percentages are much higher than those reported in this study probably due to their different geographical location, study time difference and the antibiotic-use rates.

In this study, there was significant association between β-lactamases production and site of infection ($P=0.030$). *P. aeruginosa* isolated from blood showed the highest production of *bla_{TEM}*, *bla_{SHV}*, *bla_{CTXM-P}*, *bla_{VEB}* and *bla_{OXA-1}* genes production followed by ear swab, urine, sputum and wound swab. This result agrees with a study in India reported by Basak *et al.* (2012)⁴⁸ where the highest β-lactamases producing *P. aeruginosa* isolates were from blood, but disagrees with Azizi *et al.* (2015)⁴⁹ in Iran who found that highest production was in *P. aeruginosa* isolated from wound followed by urine, sputum and blood. There was insignificant association between

the presence of class C β -lactamase genes and site of infection ($P=0.215$) found in the present study. The highest frequency of class C β -lactamases genes in *P. aeruginosa* were isolated from blood followed by urine, ear swab, wound swab and sputum. These results agree with the study in India reported by Basak *et al.* (2012)⁴⁸ in that the highest percentage of class C β -lactamase genes in *P. aeruginosa* were found in blood.

In the present study, there were four clinical isolates phenotypically sensitive to third generation cephalosporins (Ceftazidime and Cefotaxime) and genotypically positive for β -lactamases genes. This result indicates that *P. aeruginosa* may carry hidden unexpressed genes that could be detected through molecular techniques. This result agrees with a study in India reported by Bajpai *et al.* (2017)⁵⁰ where out of 38 phenotypically β -lactamases-negative isolates, 20 isolates were positive for β -lactamases genes.

In this study, the frequency of pigment producing *P. aeruginosa* isolates was 67.5%. In a study in India a higher percentage was reported where 82.5% of *P. aeruginosa* were pigment producers (Finlayson and Brown, 2011)⁵¹. The present study revealed that there was no relationship between pigment production and pattern of antimicrobial resistance, except in Chloramphenicol ($P=0.02$) and Cefotaxime ($P=0.00$).

In this study, the relationship between pigment production and site of infection was significant ($P=0.000$). *P. aeruginosa* isolated from wound infections were the highest pigment producing isolates followed by isolates from blood, urine and sputum. There was no pigment production in *P. aeruginosa* isolated from ear infections in this study.

The variations between the results of this study and other reports could be attributed to the difference in antibiotic usage patterns in each region, economical causes, geographical differences, sample size, differences in time in which the studies were performed, and study population. Despite the significance of the present study, there were limitations that should be avoided in future studies, such as the small sample size, phenotypic detection of β -lactamases, coverage of other β -lactamase classes, and gene sequencing should be done in order to confirm and to identify all the genes that are carried by *P. aeruginosa* strains in Sudan.

Conclusion

This study is of great importance as it raises attention to the existing problem of resistance to β -lactams in *P. aeruginosa* in Sudan. This study confirms the reports that a number of antibiotics are becoming useless for treating this problematic bacterium, since all the strains of *P. aeruginosa* isolates in this study were resistant to Amoxicillin and Amoxicillin/clavulanate. The best antibiotic sensitivity results obtained in this study were those of Imipenem, followed by Gentamicin and Ciprofloxacin. Moreover, *P. aeruginosa* isolates showed an increased rate of β -lactamase production with co-resistance with other classes of antibiotics. Of interest is the finding that clinical isolates were resistant phenotypically in high frequencies to Amoxicillin, Amoxicillin/clavulanate and a third generation antibiotic, Cephalosporin, and showed negative results genotypically, indicating that resistance to this family of antibiotics also exist by resistance mechanisms other than β -lactamases production. Also, our PCR results revealed that *P. aeruginosa* possesses hidden β -lactamases genes that can't be detected phenotypically. Finally, this study highlighted for the first time the problem of misidentification of *P. aeruginosa* and other microorganisms in Khartoum hospitals as only 80 out of the 120 alleged isolates were confirmed to be *P. aeruginosa* through PCR.

Data availability

Underlying data

Figshare: SPSS, <https://doi.org/10.6084/m9.figshare.12453287.v2>⁵¹

This project contains the following underlying data:

- SPSS. sav (Result sheet for beta-lactamases detection and sensitivity testing)
- Data Dictionary. docx

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

Acknowledgements

Deep thanks to all the Microbiology Department team at Sudan University of Science and Technology for their significant help during the study. We are especially thankful to Mariam Awad Ahmed Suliman for her kind support and great advice throughout the study and very special thanks to Dr. Ahmed Bakheet Abd Alla for his kind guidance and support.

References

- Forbes BA, Sahm DF, Weissfeld AS: **Study guide for Bailey & Scott's diagnostic microbiology**. Mosby USA; 2007.
[Reference Source](#)
- Glupczynski Y, Bogaerts P, Deplano A, *et al.*: **Detection and characterization of class A extended-spectrum- β -lactamase-producing *Pseudomonas aeruginosa* isolates in Belgian hospitals**. *J Antimicrob Chemother.* 2010; **65**(5): 866–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lin SP, Liu MF, Lin CF, *et al.*: **Phenotypic detection and polymerase chain reaction screening of extended-spectrum β -lactamases produced by *Pseudomonas aeruginosa* isolates**. *J Microbiol Immunol Infect.* 2012; **45**(3): 200–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Agouri SR: **Genetic characterisation of MBL positive pseudomonas and Enterobacteriaceae**. Cardiff University; 2014.
[Reference Source](#)
- Beta-lactamases B, d Inhibitor Resistant T: **Extended spectrum beta-lactamases**.

6. Ghafourian S, Sadeghifard N, Soheili S, *et al.*: **Extended spectrum beta-lactamases: definition, classification and epidemiology.** *Curr Issues Mol Biol.* 2014; **17**(1): 11–22.
[PubMed Abstract](#)
7. Mshana S: **Department of Microbiology/Immunology, Weill Bugando University College of Health Sciences a Constituent College of St Augustine University of Tanzania: St. Augustine University of Tanzania.** 2011.
[Reference Source](#)
8. Poirel L, Weldhagen GF, De Champs C, *et al.*: **A nosocomial outbreak of *Pseudomonas aeruginosa* isolates expressing the extended-spectrum β -lactamase GES-2 in South Africa.** *J Antimicrob Chemother.* 2002; **49**(3): 561–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Lee S, Park YJ, Kim M, *et al.*: **Prevalence of Ambler class A and D β -lactamases among clinical isolates of *Pseudomonas aeruginosa* in Korea.** *J Antimicrob Chemother.* 2005; **56**(1): 122–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Jiang X, Zhang Z, Li M, *et al.*: **Detection of extended-spectrum β -lactamases in clinical isolates of *Pseudomonas aeruginosa*.** *Antimicrob Agents Chemother.* 2006; **50**(9): 2990–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Bahmani N, Ramazanadeh R: **Detection of SHV type extended-spectrum β -lactamase and risk factors in *pseudomonas aeruginosa* clinical isolates.** *Pak J Med Sci.* 2013; **29**(3): 788–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Vala MH, Hallajzadeh M, Hashemi A, *et al.*: **Detection of Ambler class A, B and D β -lactamases among *pseudomonas aeruginosa* and *Acinetobacter baumannii* clinical isolates from burn patients.** *Ann Burns Fire Disasters.* 2014; **27**(1): 8–13.
[PubMed Abstract](#) | [Free Full Text](#)
13. Chen Z, Niu H, Chen G, *et al.*: **Prevalence of ESBLs-producing *pseudomonas aeruginosa* isolates from different wards in a Chinese teaching hospital.** *Int J Clin Exp Med.* 2015; **8**(10): 19400–5.
[PubMed Abstract](#) | [Free Full Text](#)
14. Elhariri M, Hamza D, Elhelw R, *et al.*: **Extended-spectrum beta-lactamase-producing *Pseudomonas aeruginosa* in camel in Egypt: potential human hazard.** *Ann Clin Microbiol Antimicrob.* 2017; **16**(1): 21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Jamali S, Shahid M, Sobia F, *et al.*: **Phenotypic and molecular characterization of cefotaximes, temoniera, and sulhydryl variable β -lactamases in *Pseudomonas* and *Acinetobacter* isolates in an Indian tertiary health-care center.** *Indian J Pathol Microbiol.* 2017; **60**(2): 196–205.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Peymani A, Naserpour-Farivar T, Zare E, *et al.*: **Distribution of *bla*_{TEM}, *bla*_{SHV} and *bla*_{CTX-M} genes among ESBL-producing *P. aeruginosa* isolated from Qazvin and Tehran hospitals, Iran.** *J Prev Med Hyg.* 2017; **58**(2): E155.
[PubMed Abstract](#) | [Free Full Text](#)
17. Kaur A, Singh S: **Prevalence of Extended Spectrum Betalactamase (ESBL) and Metallobetalactamase (MBL) Producing *Pseudomonas aeruginosa* and *Acinetobacter baumannii* Isolated from Various Clinical Samples.** *J Pathog.* 2018; **2018**: 6845985.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Fouch S: **Molecular epidemiological study of extended spectrum betalactamase (ESBL) producing bacteria from teaching and district general hospitals within Hampshire.** University of Portsmouth; 2015.
[Reference Source](#)
19. Tam V, Schilling A, LaRocco M, *et al.*: **Prevalence of AmpC over-expression in bloodstream isolates of *Pseudomonas aeruginosa*.** *Clin Microbiol Infect.* 2007; **13**(4): 413–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Tomás M, Doumith M, Warner M, *et al.*: **Efflux pumps, OprD porin, AmpC β -lactamase, and multiresistance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients.** *Antimicrob Agents Chemother.* 2010; **54**(5): 2219–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Bhattacharjee A, Anupurba S, Gaur A, *et al.*: **Prevalence of inducible AmpC β -lactamase-producing *Pseudomonas aeruginosa* in a tertiary care hospital in northern India.** *Indian J Med Microbiol.* 2008; **26**(1): 89–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Lee JY, Ko KS: **OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo- β -lactamases in carbapenem-resistant *Pseudomonas aeruginosa* isolates from South Korea.** *Int J Antimicrob Agents.* 2012; **40**(2): 168–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Mirsalehian A, Kalantar-Neyestanaki D, Nourijelyani K, *et al.*: **Detection of AmpC- β -lactamases producing isolates among carbapenem resistant *P. aeruginosa* isolated from burn patient.** *Iran J Microbiol.* 2014; **6**(5): 306–10.
[PubMed Abstract](#) | [Free Full Text](#)
24. Neyestanaki DK, Mirsalehian A, Rezagholizadeh F, *et al.*: **Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant *Pseudomonas aeruginosa* isolated from burn patients.** *Burns.* 2014; **40**(8): 1556–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Berrazeg M, Jeannot K, Enguéné VYN, *et al.*: **Mutations in β -lactamase AmpC increase resistance of *Pseudomonas aeruginosa* isolates to antipseudomonal cephalosporins.** *Antimicrob Agents Chemother.* 2015; **59**(10): 6248–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Calvopiña K, Silva MG, Vallejo MJ, *et al.*: **AmpC, oprD Expression Analysis in β -lactam Resistant *Pseudomonas aeruginosa* Clinical Isolates 1 from a Tertiary Level Hospital in Ecuador.** *Rev Ecuat Med Cienc Biol.* 2017; **38**(1): 35–43.
[Reference Source](#)
27. Oliveira LG, Ferreira LGR, Nascimento AMA, *et al.*: **Antibiotic resistance profile and occurrence of AmpC between *Pseudomonas aeruginosa* isolated from a domestic full-scale WWTP in southeast Brazil.** *Water Sci Technol.* 2017; **2017**(1): 108–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Jalali HR, Pourbakhsh A, Fallah F, *et al.*: **Genotyping of Virulence Factors of Uropathogenic *Escherichia coli* by PCR.** *Novelty in Biomedicine.* 2015; **3**(4): 177–81.
[Reference Source](#)
29. Khattab M, Nour M, ElSheshtawy N: **Genetic identification of *Pseudomonas aeruginosa* virulence genes among different isolates.** *J Microb Biochem Technol.* 2015; **7**(5): 274–7.
[Publisher Full Text](#)
30. Mathlouthi N, Al-Bayssari C, El Salabi A, *et al.*: **Carbapenemases and extended-spectrum β -lactamases producing Enterobacteriaceae isolated from Tunisian and Libyan hospitals.** *J Infect Dev Ctries.* 2016; **10**(7): 718–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Saishu N, Ozaki H, Murase T: **CTX-M-type extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* isolated from cases of bovine mastitis in Japan.** *J Vet Med Sci.* 2014; **76**(8): 1153–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Hujer AM, Page MG, Helfand MS, *et al.*: **Development of a sensitive and specific enzyme-linked immunosorbent assay for detecting and quantifying CMY-2 and SHV beta-lactamases.** *J Clin Microbiol.* 2002; **40**(6): 1947–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Liu XQ, Liu YR: **Detection and genotype analysis of AmpC β -lactamase in *Klebsiella pneumoniae* from tertiary hospitals.** *Exp Ther Med.* 2016; **12**(1): 480–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Finlayson E, Brown P: **Comparison of antibiotic resistance and virulence factors in pigmented and non-pigmented *Pseudomonas aeruginosa*.** *West Indian Med J.* 2011; **60**(1): 24–32.
[PubMed Abstract](#)
35. Magoué CL, Melin P, Gangoue-Pieboji J, *et al.*: **Prevalence and spread of extended-spectrum β -lactamase-producing Enterobacteriaceae in Ngaoundere, Cameroon.** *Clin Microbiol Infect.* 2013; **19**(9): E416–E20.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Altayb HN, Siddig MA, El Amin NM, *et al.*: **Molecular Characterization of CTX-M ESBLs among Pathogenic Enterobacteriaceae isolated from different regions in Sudan.** 2018.
[Reference Source](#)
37. Qureshi MA, Bhatnagar RK: **Phenotypic Characterization of ESBL, AmpC and MBL Producers among the Clinical Isolates of Multidrug Resistant *Pseudomonas aeruginosa*.** *Int J Curr Microbiol App Sci.* 2016; **5**(10): 749–58.
[Publisher Full Text](#)
38. Gupta R, Malik A, Rizvi M, *et al.*: **Incidence of multidrug-resistant *Pseudomonas* spp. In ICU patients with special reference to ESBL, AMPC, MBL and biofilm production.** *J Glob Infect Dis.* 2016; **8**(1): 25–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Salah M, Azab M, Halaby H, *et al.*: **Mutations in β -lactamases detected in multidrug resistant gram negative bacteria isolated from community acquired urinary tract infections in Assiut, Egypt.** *Afr J Microbiol Res.* 2016; **10**(46): 1938–43.
[Publisher Full Text](#)
40. Rafiee R, Eftekhari F, Tabatabaei SA, *et al.*: **Prevalence of extended-spectrum and metallo β -lactamase production in AmpC β -lactamase producing *Pseudomonas aeruginosa* isolates from burns.** *Jundishapur J Microbiol.* 2014; **7**(9): e16436.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Sales A, Fathi R, Mobaieen H: **Molecular Study of the Prevalence of CTX-M1, CTX-M2, CTXM3 in *Pseudomonas aeruginosa* Isolated from Clinical Samples in Tabriz Town, Iran.** *Electronic J Biol.* 2017; **13**(3): 253–259.
[Reference Source](#)
42. Bokaeian M, Zahedani SS, Bajgiran MS, *et al.*: **Frequency of PER, VEB, SHV, TEM and CTX-M genes in resistant strains of *Pseudomonas aeruginosa* producing extended spectrum β -lactamases.** *Jundishapur J Microbiol.* 2014; **8**(1): e13783.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Katvoravutthichai C, Boonbumrung K, Tiyaawitsuri R: **Prevalence of β -lactamase classes A, C, and D among clinical isolates of *Pseudomonas aeruginosa* from a tertiary-level hospital in Bangkok, Thailand.** *Genet Mol Res.* 2016; **15**(3).
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Awad A, Eltayeb I, Baraka O: **Changing antibiotics prescribing practices in health centers of Khartoum State, Sudan.** *Eur J Clin Pharmacol.* 2006; **62**(2): 135–42.
[PubMed Abstract](#) | [Publisher Full Text](#)

45. Ahmad M, Hassan M, Khalid A, *et al.*: **Prevalence of extended spectrum β -lactamase and antimicrobial susceptibility pattern of clinical isolates of *Pseudomonas* from patients of Khyber Pakhtunkhwa, Pakistan.** *Biomed Res Int.* 2016; **2016**: 6068429.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Altom RB, Ahmed ST: **Antimicrobial Susceptibility of Clinical Isolates of *Pseudomonas aeruginosa* to Aminoglycosides and Imipenem.** B. Sc dissertation. Sudan University of Science and Technology. 2015.
47. Albadawi SA: **Determination of Antimicrobial Susceptibility of *Pseudomonas aeruginosa* Isolated from Sudanese Patients.** Post graduate Diploma dissertation. Sudan University of Science and Technology. 2010.
48. Basak S, Attal RO, Rajurkar M: ***Pseudomonas aeruginosa* and newer β -lactamases: an emerging resistance threat.** *Infection Control-Updates: InTech.* 2012.
[Publisher Full Text](#)
49. Azizi H, Kheirandish F, Mirzaei M: **Frequency of Extended-Spectrum Beta-Lactamase (ESBLs)-Multidrug Resistance Produced by *Pseudomonas aeruginosa* Isolated from Clinical Specimens in Khorramabad City, Iran.** *Br Microbiol Res J.* 2015; **5**(6): 490.
[Publisher Full Text](#)
50. Bajpai T, Pandey M, Varma M, *et al.*: **Prevalence of TEM, SHV, and CTX-M Beta-Lactamase genes in the urinary isolates of a tertiary care hospital.** *Avicenna J Med.* 2017; **7**(1): 12–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Abdelrahman DN, Taha AA, Dafaallah MM, *et al.*: **SPSS.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.12453287.v2>

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 14 December 2020

<https://doi.org/10.5256/f1000research.29444.r74648>

© 2020 Qasim M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Muhammad Qasim

Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan

The manuscript "Extended spectrum β -lactamases and class C β -lactamases gene frequency in *Pseudomonas aeruginosa* isolated from various clinical specimens in Khartoum State, Sudan: a cross sectional study" describe important findings on drug resistance (ESBL and Class C Beta lactamases) of *P. aeruginosa* in Khartoum State, Sudan. The author claimed the study to be the first one to describe the exact frequency of ESBL producing *P. aeruginosa* in Khartoum, Sudan.

On the whole the research is scientifically carried out and written. Following are few minor suggestions

- In the abstract section, the author has mentioned that 40 isolates were other bacterial species. I think the objective of the study is the molecular detection of beta lactamases in *P.aeruginosa* so there is no need mention about other bacterial species.
- The statement "121 *Ps. aeruginosa* clinical isolates from various clinical specimens were used in this cross-sectional study conducted in Khartoum State. A total of 80 isolates were confirmed as *Ps. aeruginosa* through conventional identification methods and species specific primers" is really confusing. If 80 *P. aeruginosa* isolates were finally analyzed for drug resistance then there no need to state 121 *P. aeruginosa* clinical isolates.
- As mentioned above the focus of manuscript is drug resistance in *P. aeruginosa*, so the irrelevant information such as Pyocyanin pigment production should be deleted.
- Though in methodology section, the author has claimed statistical tests (chi square, p value), but there is no information on statistical tests in figures. I think statistical values should be included in figures.
- In all tables, please proper define the abbreviations, number and percentage (n(%)) in foot note.
- Figures should be properly labeled (Frequency (n)).

- The percentage should be added in all tables, as it will help the readers to understand and interpret the tables in better way.
- Some of the references are inconsistent/incomplete which should be arranged as per journal format.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Medical Microbiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 19 Dec 2020

Dina Naser, Central Laboratory, Khartoum, Sudan

Thank you for these comments, minor changes have been done following the reviewer's comments. Changes include specifying the final included sample size, addition of results percentages to the tables with minor edits in the figures titles and in the abstract the Beta-lactamases genes naming changed according to the title.

Competing Interests: No competing interests were disclosed.

Reviewer Report 22 September 2020

<https://doi.org/10.5256/f1000research.29444.r71387>

© 2020 Kobayashi N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nobumichi Kobayashi

Department of Hygiene, Sapporo Medical University School of Medicine, Sapporo, Japan

The revised version is described appropriately using correct scientific terms.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: microbiology, public health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 26 August 2020

<https://doi.org/10.5256/f1000research.27382.r68073>

© 2020 Kobayashi N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nobumichi Kobayashi

Department of Hygiene, Sapporo Medical University School of Medicine, Sapporo, Japan

This is a kind of primitive study that provides only limited information. Only importance is that this study was done in Sudan. However, still number of isolates were low, and errors in descriptions of technical terms are found in this manuscript.

1. Abstract: Number of *P. aeruginosa* should be written as "80". "121" should not appear here, because 41 isolates were not *P. aeruginosa*.
2. "*Ps. aeruginosa*" should be corrected as "*P. aeruginosa*", as formal abbreviation.
3. Amoxyclav may be a commercial name of the drug. It should be written as general name. Maybe it is "amoxicillin/clavulanate".
4. Authors may have serious misunderstanding regarding the term of ESBL. NOT all of TEM, SHV, OXA type beta-lactamases are ESBL. TEM-1, 2, SHV-1, OXA-1 are not ESBL. Other subtypes of TEM, SHV, and OXA are called as "ESBL". Those subtypes can be identified only by sequencing of full-length ORF of these genes. In this manuscript, only CTX-M type gene can be called as "ESBL". However, it is not sure that TEM, SHV, OXA type genes are ESBL genes or not, because sequence was not determined. In this regard, this manuscript must be revised substantially. Authors can mention CTX-M as ESBL, others should not be referred as ESBL, but just individual enzyme names, e.g., "TEM gene". According to this alteration, whole manuscript should be rewritten.
5. CTX-M-1 should be written as "CTX-M-1 group". CTX-M types cannot be determined by only PCR. Authors should read and study literature on ESBL and beta-lactamases of bacteria, to exactly understand their nomenclature and definition.
6. Table 3 cannot be understood. Authors should make a table to show combination pattern of beta-lactamases and their frequency.
7. Figure 5: "Class AmpC genes" is wrong. It should be "Class C beta-lactamase" or "AmpC gene". In this case, "AmpC gene" is better.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: microbiology, public health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Author Response 06 Sep 2020

Dina Naser, Central Laboratory, Khartoum, Sudan

- Classification of *bla*_{TEM}, *bla*_{SHV}, *bla*_{CTXM-1}, *bla*_{VEB} and *bla*_{OXA-1} changed from ESBLs to β -lactamases enzymes generally, they named in the draft as individual genes and classified as **β -lactamases** group.

This change applied in the whole draft including tables and figures, even the title changed to " **β -lactamases (*bla*_{TEM}, *bla*_{SHV}, *bla*_{CTXM-1}, *bla*_{VEB}, *bla*_{OXA-1}) and class C β -lactamases gene frequency in *Pseudomonas aeruginosa* isolated from various clinical specimens in Khartoum State, Sudan: a cross sectional study**"

- In abstract: The sample size mentioned as the confirmed **80** *P. aeruginosa* isolates, the remaining **41** isolate other than *P. aeruginosa* deleted.
- All "*Ps. aeruginosa*" in the text changed to "*P. aeruginosa*" as formal abbreviation.
- All "**Amoxyclav**" in the text changed to "**amoxicillin/clavulanate**"
- "**Class AmpC genes**" in figure 5 changed to "**Class C β -lactamase**"
- "**ESBLs**" changed to " **β -lactamases**" in figure 3 and figure 5.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research